
|
Incidence
and Determinants of Bacterial Infections in HIV-Positive Patients
Receiving Anti-Pneumocystis carinii/Toxoplasma gondii Primary
Prophylaxis Within a Randomized Clinical Trial [Murri
R et al. JAIDS 2001; 27: 49]: The authors examine the incidence
of bacterial infections (bacteremia, pneumonia, sinusitis and otitis)
in patients randomized to TMP-SMX or dapsone-pyrimethamine for primary
prophylaxis of PCP and TE. The total participants were 244, and
the frequency of bacterial infections complications during the two-year
follow-up was bacteremia - 22, pneumonia - 63 and sinusitis/otitis
- 39. These complications were equally divided in the two groups.
The authors conclude that TMP-SMX does not protect against bacterial
infections.
Comment: This study seems to defy both logic and the results
of several randomized trials of PCP prophylaxis that have consistently
shown a reduction in bacterial infections [NEJM 1992;327:
1842; AIDS 1993;7:1687; Lancet 1999; 353: 1463]. The
authors point out that their results are consistent with some, though
not all, prior studies and that the antibacterial activity of dapsone
and pyrimethamine is not known.
posted
7/3/2001
|

|